Analyzing Analyst Recommendations: Cue Biopharma, Inc. (CUE), American Renal Associates Holdings, Inc. (ARA)

Cue Biopharma, Inc. (NASDAQ:CUE) tinted gains of +5.73% (+0.35 points) to US$6.46. The volume of 0.07 Million shares climbed down over an trading activity of 98.24 Million shares. EPS ratio determined by looking at last 12 month figures is -1.99. Over the same time span, the stock marked US$17.99 as its best level and the lowest price reached was US$4.16. The corporation has a market cap of US$126.49 Million.

Cue Biopharma, Inc. (NASDAQ:CUE)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -67.9 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 22.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

American Renal Associates Holdings, Inc. (NYSE:ARA) is worth US$397.06 Million and has recently risen 5.65% to US$12.9. The latest exchange of 0.11 Million shares is below its average trading activity of 122.12 Million shares. The day began at US$12.31 but the price moved to US$12.25 at one point during the trading and finally capitulating to a session high of US$12.95. The stock tapped a 52-week high of US$24.07 while the mean 12-month price target for the shares is US$15.58.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 0.49. For the past 5 years, the company’s revenue has grown 12.1%, while the company’s earnings per share has grown -24.2%. With an institutional ownership near 98%, it carries an earnings per share ratio of -0.54.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.17.